Safety and efficacy of lorcaserin: A combined analysis of the BLOOM and BLOSSOM trials

Postgraduate Medicine

Volumn 126, Issue 6, 2014, Pages 7-18

  Aronne, Louis ^a   Shanahan, William ^b   Fain, Randi ^c   Glicklich, Alan ^b   Soliman, William ^c   Li, Yuhan ^c   Smith, Steven ^d,e  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b ARENA PHARMACEUTICALS   (United States)

^c EISAI INC   (United States)

^d BURNHAM INSTITUTE   (United States)

^e FLORIDA HOSPITAL   (United States)

Author keywords

BLOOM; BLOSSOM; Lorcaserin; Obesity; Pharmacotherapy

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LORCASERIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; ANTIOBESITY AGENT; BENZAZEPINE DERIVATIVE; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; SEROTONIN 2 AGONIST;

ARTHRALGIA; ARTICLE; BACKACHE; BRONCHITIS; CONSTIPATION; COUGHING; DIARRHEA; DIET; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; EXERCISE; FATIGUE; HEADACHE; HUMAN; INFLUENZA; INSOMNIA; LIMB PAIN; MUSCLE STRAIN; NAUSEA; OBESITY; OROPHARYNX PAIN; PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VALVULAR HEART DISEASE; VIRAL GASTROENTERITIS; VOMITING; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; XEROSTOMIA; ADOLESCENT; ADULT; AGED; BLOOD; BLOOD PRESSURE; CHEMICALLY INDUCED; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; FEMALE; GLUCOSE BLOOD LEVEL; HEART RATE; LIFESTYLE; MALE; METABOLISM; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-OBESITY AGENTS; BENZAZEPINES; BLOOD GLUCOSE; BLOOD PRESSURE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FEMALE; HEADACHE; HEART RATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; NASOPHARYNGITIS; OBESITY; QUALITY OF LIFE; RESPIRATORY TRACT INFECTIONS; SEROTONIN 5-HT2 RECEPTOR AGONISTS; TRIGLYCERIDES; WAIST CIRCUMFERENCE; WEIGHT LOSS; YOUNG ADULT;

EID: 84922392384     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2014.10.2817     Document Type: Article

References (37)

1. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity among adults: United States, 2011–2012. NCHS Data Brief. 2013;(131):1–8.
2. Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA. 2014;311(1):74–86.
3. Wadden TA, Volger S, Tsai AG, et al. POWER-UP Research Group. Managing obesity in primary care practice: an overview and perspective from the POWER-UP study. Int J Obes (Lond). 2013;37(Suppl 1): S3–S11.
4. Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597–1604.
5. Chan JL, Heist K, DePaoli AM, Veldhuis JD, Mantzoros CS. The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. J Clin Invest. 2003;111(9):1409–1421.
6. Garfield AS, Heisler LK. Pharmacological targeting of the serotonergic system for the treatment of obesity. J Physiol. 2009;587(Pt 1):49–60.
7. Lam DD, Przydzial MJ, Ridley SH, et al. Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors. Endocrinology. 2008;149(3):1323–1328.
8. Halford JC, Boyland EJ, Lawton CL, Blundell JE, Harrold JA. Serotonergic anti-obesity agents: past experience and future prospects. Drugs. 2011;71(17):2247–2255.
9. Thomsen WJ, Grottick AJ, Menzaghi F, et al. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther. 2008;325(2):577–587.
10. Phelan S, Nallari M, Darroch FE, Wing RR. What do physicians recommend to their overweight and obese patients? J Am Board Fam Med. 2009;22(2):115–122.
11. Salinas GD, Glauser TA, Williamson JC, Rao G, Abdolrasulnia M. Primary care physician attitudes and practice patterns in the management of obese adults: results from a national survey. Postgrad Med. 2011;123(5):214–219.
12. Heisler LK, Jobst EE, Sutton GM, et al. Serotonin reciprocally regulates melanocortin neurons to modulate food intake. Neuron. 2006;51(2):239–249.
13. Martin CK, Redman LM, Zhang J, et al. Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure. J Clin Endocrinol Metab. 2011;96(3):837–845.
14. US Food and Drug Administration. BELVIQ (lorcaserin hydrochloride) Highlights of Prescribing Information. https://www.belviq.com/pdf/ Belviq_Prescribing_information.pdf. Revised August 2012. Accessed September 10, 2014.
15. Smith SR, Weissman NJ, Anderson CM, et al. Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363(3):245–256.
16. Fidler MC, Sanchez M, Raether B, et al. BLOSSOM Clinical Trial Group. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96(10):3067–3077.
17. Weissman NJ, Sanchez M, Koch GG, Smith SR, Shanahan WR, Anderson CM. Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials. Circ Cardiovasc Imaging. 2013;6(4):560–567.
18. O’Neil PM, Smith SR, Weissman NJ, et al. Randomized placebocontrolled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012;20(7):1426–1436.
19. Apovian CM, Aronne L, Rubino D, et al. COR-II Study Group. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013;21(5):935–943.
20. Greenway FL, Fujioka K, Plodkowski RA, et al. COR-I Study Group. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial [published correction appears in Lancet. 2010;376(9741):594, and Lancet. 2010;376(9750):1392]. Lancet. 2010;376(9741):595–605.
21. Dalle Grave R, Calugi S, Molinari E, et al. QUOVADIS Study Group. Weight loss expectations in obese patients and treatment attrition: an observational multicenter study. Obes Res. 2005;13(11):1961–1969.
22. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(25 Suppl 2):S102–S138.
23. Knowler WC, Barrett-Connor E, Fowler SE, et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.
24. Tuomilehto J, Lindström J, Eriksson JG, et al. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343–1350.
25. Grimm RH Jr, Cohen JD, Smith WM, Falvo-Gerard L, Neaton JD. Hypertension management in the Multiple Risk Factor Intervention Trial (MRFIT). Six-year intervention results for men in special intervention and usual care groups. Arch Intern Med. 1985;145(7):1191–1199.
26. Wassertheil-Smoller S, Blaufox MD, Oberman AS, Langford HG, Davis BR, Wylie-Rosett J. The Trial of Antihypertensive Interventions and Management (TAIM) study. Adequate weight loss, alone and combined with drug therapy in the treatment of mild hypertension. Arch Intern Med. 1992;152(1):131–136.
27. Whelton PK, Appel LJ, Espeland MA, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group [published correction appears in JAMA. 1998;279(24):1954]. JAMA. 1998;279(11):839–846.
28. Després JP. Body fat distribution and risk of cardiovascular disease: an update. Circulation. 2012;126(10):1301–1313.
29. Lichtenstein AH. Thematic review series: patient-oriented research. Dietary fat, carbohydrate, and protein: effects on plasma lipoprotein patterns. J Lipid Res. 2006;47(8):1661–1667.
30. Nordmann AJ, Nordmann A, Briel M, et al. Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. Arch Intern Med. 2006;166(3):285–293.
31. Wood RJ, Volek JS, Liu Y, Shachter NS, Contois JH, Fernandez ML. Carbohydrate restriction alters lipoprotein metabolism by modifying VLDL, LDL, and HDL subfraction distribution and size in overweight men. J Nutr. 2006;136(2):384–389.
32. Gardin JM, Schumacher D, Constantine G, Davis KD, Leung C, Reid CL. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA. 2000;283(13):1703–1709.
33. James WP, Caterson ID, Coutinho W, et al. SCOUT Investigators. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363(10):905–917.
34. Foster GD, Wadden TA, Makris AP, et al. Primary care physicians’ attitudes about obesity and its treatment. Obes Res. 2003;11(10):1168–1177.
35. Heilbronn LK, de Jonge L, Frisard MI, et al. Pennington CALERIE Team. Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: a randomized controlled trial [published correction appears in JAMA. 2006;295(21):2482]. JAMA. 2006;295(13):1539–1548.
36. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J; RIONorth America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial [published correction appears in JAMA. 2006;295(11):1252]. JAMA. 2006;295(7):761–775.
37. Fabricatore AN, Wadden TA, Moore RH, et al. Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis. Obes Rev. 2009;10(3):333–341.